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Efficacy and safety of albendazole and high-dose ivermectin co-administration in school-
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Key Points. The combination of albendazole and high-dose ivermectin in this randomized 
clinical trial demonstrated significant superiority and good tolerability for the treatment of 
Trichuris trichiura infections compared to albendazole monotherapy, the current standard of 






















The efficacy of currently available anthelminthics against Trichuris trichiura infections is 
significatively lower than for other soil-transmitted helminths (STH). The combination of 
ivermectin (IVM) and albendazole (ALB) has shown significant improvements in efficacy.  
 
Methods 
Safety and efficacy randomized controlled clinical trial comparing 3 experimental regimens 
against ALB monotherapy for the treatment of T. trichiura infections in northern Honduras. 
Infected children were randomized to one of the following treatments: (Arm 1) single-dose 
ALB 400 mg; (Arm 2) single-dose ALB 400 mg/IVM 600 μg/kg; (Arm 3) ALB 400 mg for 3 
consecutive days; or (Arm 4) ALB 400 mg/IVM 600 μg/kg for 3 consecutive days. Efficacy 
was measured through egg reduction rate (ERR) and cure rate (CR), both assessed 14-21 days 
after treatment using the Kato-Katz method. Safety was evaluated by analyzing the frequency 
and severity of adverse events. 
 
Results 
A total of 176 children were randomized to one of the 4 treatment arms, 117 completed 
treatment and follow-up. The ERR for Arms 1 to 4 were: 47.7%, 96.7%, 72.1% and 100%, 
respectively; with p-values <0.001 between IVM groups and ALB only arms. The CRs were 
4.2%, 88.6%, 33.3% and 100%, respectively. A total of 48 (85.4% mild) AEs were reported 























The combined use of ALB and high-dose IVM is a highly effective and well tolerated 
treatment for the treatment of T. trichiura infections offering a significantly improved 
treatment for the control of this infection. 
 























Human infections by Trichuris trichiura are still widespread in tropical and subtropical 
impoverished regions of the world, with an estimated prevalence of over 460 million cases 
affecting mostly school-age children [1, 2]. Although commonly asymptomatic, the infection 
can cause asthenia, abdominal pain, diarrhea, anemia, and the more severe Trichuris 
dysentery syndrome [1]. Chronicity of these infections can affect cognition and school 
performance [3]. Trichuriasis is included in the group of soil-transmitted helminths (STH) 
infections targeted for control by the WHO led strategy, which recommends preventive 
chemotherapy (PC) through mass drug administration (MDA) of benzimidazoles for school 
and pre-school age children in communities with an STH prevalence ≥20% [4] . Since the 
introduction of these large scale programs in 2012, over 2.8 billion tablets of these drugs have 
been distributed for their implementation [5]; still, the Global Burden of Disease Study 
estimated an almost no reduction in the prevalence of T. trichiura [2]. 
The efficacy of currently available anthelminthic drugs against T. trichiura is significantly 
lower than for other STH such as Ascaris lumbricoides and hookworms. In a systematic 
review, the efficacy of albendazole (ALB) in single-dose regimens was calculated to produce 
cure rates (CR) of 31% (95%CI 21-42), and egg reduction rates (ERR) of 50% (95%CI 39-
61). For mebendazole (MEB), the CR was 42% (95%CI 26-60) and ERR 66% (95%CI 55-
77) [6]. As an additional concern, the same systematic review identified significantly reduced 
CRs for both drugs in studies published after the year 2000. Further, modelling studies 
estimating the number of MDA rounds required for T. trichiura control, concluded that given 
the current effectiveness of these drugs, breaking transmission for this parasite would not be 
attainable [7]. Added to improvements in drug efficacy, provision of adequate water and 




















The addition of ivermectin (IVM) to either ALB or MEB treatment has shown significant, 
although suboptimal, improvements in efficacy compared to either drug alone. Such 
combination is promising since IVM is also effective for Strongyloides stercoralis and other 
neglected tropical diseases (NTDs) such as lymphatic filariasis, onchocerciasis, and scabies 
[8, 9]. With a favorable safety profile and a wide therapeutic index [10], IVM is currently 
prescribed in weight, or height, based dosing regimen, unlike ALB or MEB which are 
prescribed in fixed doses for any person ≥2 years old.  This study presents safety and efficacy 
results of a trial comparing 3 experimental regimens that tested multiple-day regimens and 
high-dose IVM drug combinations against ALB monotherapy for the treatment of T. trichiura 




Phase II randomized, open label, controlled, outcome assessor blinded, clinical trial. 
Ethical approvals 
The study received clearance from the research ethics committee of the master program in 
Infectious and Zoonotic Diseases (CEI-MEIZ) at the National Autonomous University of 
Honduras, the Brock University Research Ethics Board, and the Sanitary Regulation Agency 
of Honduras. Additionally, the study was authorized by the regional office of the Honduran 
Health Ministry. Participants provided written parental consent and children’s assent (for 
children ≥ 9 years-old) prior to their enrollment. The study was registered at 























The clinical trial took place in two Honduran rural villages, La Hicaca and San Juan Pueblo. 
Both sites had been identified with STH prevalences >50% [11, 12]. In La Hicaca, sustained 
transmission of T. trichiura has been observed; with the latest study reporting >60% 
prevalence for this species [13]. 
 
Eligibility criteria 
The study included children between 2-14 years of age infected with T. trichiura and a body 
weight ≥15 kg. Exclusion criteria included: anthelminthic treatment within 3 previous 
months, allergies to anthelminthic drugs, acute clinical conditions (including gastrointestinal 
symptoms), pregnancy or puerperium. 
 
Sample size 
Sample size was calculated estimating the efficacy of the different experimental drug or 
combinations and gathering the individual samples sizes for the study. The sample size was 
calculated by a one-tail test for pairwise comparisons of the expected CR for four study 
groups — ALB, CR: 17%; ALB+IVM, CR: 55%; ALB+IVM x 3d, CR: 85%; ALB x 3d, CR: 
60% — with an overall significance level of 5% adjusted for multiple tests by Bonferroni's 
correction, 80% power and inflated for 10% lost-to-follow-up. The estimated sample size was 
of 177 participants (single dose ALB: 39, single dose ALB/IVM: 57, 3-dose ALB: 24, 3-dose 
ALB/IVM: 57). 
 
Baseline procedures to determine eligibility 
All children aged 2-14 years from La Hicaca and children enrolled in first through third grade 
in San Juan Pueblo were invited to participate in the study. Upon enrollment, weight (kg) and 




















(WAZ), and body-mass-index-for-age Z-score (BMIZ) using WHO AnthroPlus version 1.0.4 
(WHO, Geneva, Switzerland). 
To identify trichuriasis, a single fecal sample was collected from each participant and 
examined through the Kato-Katz method within 30–60 min of preparation. Quality control 
reexamination was performed in 100% of the negative and 10% of the positive samples. 
Infection intensities were classified as light, moderate, or heavy infections according to WHO 
guidelines [14]. Children whose Kato-Katz was negative for T. trichiura but positive for any 
other STH were provided 3-day ALB treatment free of charge. 
Randomization Phase 
Simple centralized randomization was performed through a computer-based random 
generated list (with varying random blocks) to assign children to one of the four treatment 
arms. Group assignments were concealed from researchers doing the diagnostic tests. 
 
Intervention 
Treatments were administered by physicians. Participants were randomly assigned to one of 
the four following treatments: (1) single-dose ALB 400 mg; (2) single-dose ALB 400 mg + 
IVM 600 µg/kg; (3) ALB 400 mg for 3 consecutive days; or (4) ALB 400 mg + IVM 600 
µg/kg for 3 consecutive days. The drugs administered were ALB 400 mg tablets and IVM 6 
mg scored tablets (Nematel™ and Iver-P™ respectively by Elea/Phoenix, Argentina). IVM 6 
mg scored tablets  were used in all cases at a dose of 0.6mg/kg/day based on baseline weight 
rounding to the lower full (6mg) or half (3mg) dose. Prior to treatment, a standard meal with 
an approximate nutritional value of 377 Cal (47% carbohydrates, 36% fat and 17% protein) 
was provided, to assure optimal systemic availability of the drugs in all participants and to 




















the end of the trial, participants remaining positive for T. trichiura received an additional 3-
day ALB 400 mg treatment. 
 
Safety Assessment  
To assess drug safety, the following data were gathered and classified according to severity: 
i) adverse events (AE) and ii) laboratory determination of ALT and AST. Physical 
examination was performed by physicians immediately before and 4 h after treatment. 
Participants were monitored for 4 h, after receiving medication in view of the proposed link 
between Cmax and toxicity for IVM [15]. A structured questionnaire to identify visual 
disturbances was included. 
Blood samples for laboratory analysis were collected 4 h after drug administration on the first 
and last day of treatment (in cases of 3-day treatment arms), and abnormalities were 
classified following the National Institute of Health (NIH) guidelines [16]. Hemoglobin 
concentrations were measured and anemia was determined based on hemoglobin values 
according to age [17]. 
 
Efficacy Assessment  
The primary outcome of this clinical trial was CR against T. trichiura at 14-21 days post-
treatment in a single Kato-Katz specimen, based on WHO Guidelines [18]. The secondary 
outcome was T. trichiura ERR at the same end-point. 
 
Drug Concentration Assessment  
To determine systemic drug concentrations from each participant at 4 h after treatment 
(approximate time to peak blood concentration for ALB and IVM in humans), 2 droplets 




















Thermo scientific USA) and dried at room temperature, placed in sealed plastic bags with 
silica gel desiccant and stored at room temperature for further HPLC analysis.  
To extract ALB/metabolites and IVM, blood samples were punched from dried blood spot 
(DBS) cards and transferred to a polypropylene tube (5 mL). The samples were spiked with 
10 µL of oxibendazole or moxidectin internal standard (IS), respectively.  Followed by 1 mL 
of acetonitrile/water (4:1 v/v). After shaking (15 min), sonication (90 min) in an ultrasonic 
bath (90 min), and centrifugation (2300 xg,10 min, 4 ºC), the liquid fraction was transferred 
to a 5-mL glass tube and evaporated to dryness under a gentle stream of dry nitrogen at 56 ºC 
in a water bath. The chromatographic conditions for ALB and IVM analysis were previously 
reported by Ceballos et al., [19] and Lifschitz et al., [20], respectively. 
A complete validation of the analytical procedures for the extraction and quantification of 
ALB and its metabolites, ALB sulphoxide (ALBSO) and ALB sulphone (ALBSO2) and IVM 
in DBS was performed. The chromatographic identification of either ALB and its metabolites 
or IVM was undertaken by comparison with retention times of pure reference standards. The 
linearity of the method was tested after elaboration of analytical calibration curves using 70 
µL drops of human blood previously fortified, transferred onto filter paper and dried for 1 h. 
The calibration curves of all analytes showed good linearity with correlation coefficients 
>0.995. The calibration range was between 0.2-2 µg/mL (ALB, ALBSO and ALBSO2) and 5-
200 ng/mL (IVM). 
The extraction efficiency of the analytes was determined by comparison of the peak areas 
from fortified blank samples with the peak areas from direct injections of equivalent 
quantities of standards. Mean absolute recovery percentages ranged between 80 and 92.1%. 
The limit of quantification defined as the lowest measured concentration with a CV <20%, 
accuracy of ± 20% and absolute recovery <70%, was 0.2 mg/mL for ALB/metabolites and 5 






















Statistical analyses were done using STATA (Stata SE version 16.1 StataCorp, USA). CRs 
were calculated as the percentage of T. trichiura positive participants at baseline who became 
egg-negative after treatment, considering a 95% confidence interval (CI). Arithmetic mean 
egg counts were calculated for each treatment arm before and after treatment to assess the 
corresponding ERR, using the following formula: ERR= (1 – [mean EPG at follow-up/mean 
EPG at baseline]) × 100. CIs for ERR were calculated using bootstrap resampling methods 
with 10,000 replicates [21]. Descriptive statistics for continuous variables and frequency 
(proportions) for categorical variables were used to describe demographic, nutritional, and 
parasitological characteristics of the studied population. A one-way ANOVA with Bonferroni 
correction was conducted to determine if nutritional characteristics differed between infection 
intensities. Differences in proportions were determined by Chi-square or Fisher exact test for 
categorical variables and Student t-test for continuous variables following a normal 
distribution. Statistical associations to determine the relationship between drug concentrations 





A total of 377 participants were assessed for eligibility: 279 from La Hicaca and 98 from San 
Juan Pueblo. Of those, 176 were enrolled and randomized to one of the 4 treatment arms 
(Figure 1). Enrollment for each arm in both communities were for arms 1 to 4, respectively: 
38 (97%), 57 (100%), 23 (96%), and 58 (102%), representing 99% of the recruitment target. 




















research team was unable to return to San Juan Pueblo and assess treatment efficacy in 53 
participants. Altogether, 117 children completed participation for the assessment of treatment 
efficacy and 117 stool samples were analyzed to determine CR and ERR (Fig 1). This was 
communicated to the Data Safety and Monitoring Board (DSMB), which based on 
preliminary analysis of the available data, recommended that the study be terminated, and 
data analyzed. 
Screened population 
Among the screened participants (N=377), trichuriasis was the most prevalent infection 
(52%), with 25% of these infections of moderate-to-heavy intensity. In terms of nutritional 
indicators, it was observed that the mean BMIZ value in participants with low intensity 
infections was 0.259 compared to a significantly lower mean value of -0.239, on those 
participants with moderate to heavy intensity (p = 0.036). No significant difference was 
identified in BMIZ score values in children with low-intensity trichuriasis versus those 
without infection (p > 0.99).  
Study Population 
The baseline characteristics of the study population included in the efficacy analysis (n=117) 
are shown in Table 1. No statistical differences were found between children randomized to 
any of the treatment arms in any of the evaluated characteristics, demonstrating the 
homogeneity between groups. 
Efficacy 
CRs and ERRs against T. trichiura for the 117 participants that completed treatment and 
follow-up are shown in Table 2. Low CR of just 4.2% (95% CI: 0.7-20.2) was observed in 
Arm 1 (ALB 400 mg single-dose). All experimental arms demonstrated significantly higher 
CRs against T. trichiura compared to Arm 1 (Table 2). ALB 400 mg during 3 consecutive 




















4.2%, p <0.05). No significant associations between intensity of infection and CRs were 
found in any of the treatment arms. 
Combined administration of IVM+ALB resulted in a significantly higher ERR compared to 
monotherapy arms, showing a reduction of 96.7% (95% CI, 96.2-96.9) and 100% (95% CI, 
96.3-100), for arm 2 and arm 4, respectively (p < 0.001). Egg reduction after treatment with 
3-day ALB was significantly higher than with single-dose (p <0.05). 
 
Drug concentrations 
Both ALB (and metabolites) and IVM were detectable 4 h after treatment. ALBSO was the 
main analyte detected in blood samples after ALB administration and IVM was detected in 
all blood samples of children from arms 2 and 4 (Table 3). 
 
Safety Assessment 
A total of 175 participants were included in the safety assessment. Thirty six (36) participants 
reported 48 adverse events (AE). No serious AEs were noted in this study and the control arm 
had the lowest frequency of AEs. The most common AEs were headache and abdominal pain, 
both with similar frequency in the experimental arms (Table 4). Photophobia was only 
reported by four participants, one of them receiving IVM. Overall, 41/48 (85.4%) of the 
reported AEs were mild and 7/48 (14.6%) were moderate. All AEs resolved without medical 
intervention within 48 h of treatment completion. Based on the physicians’ judgment and 
timing of AEs onset with respect to drug intake, it was determined that 22 out of 48 reported 
AEs (45.8%) were possibly related to treatment administration. 
Mean blood concentrations of IVM were not statistically different between children with and 
without treatment-related AEs (p = 0.8197). Similarly, no statistically significant differences 




















Conversely, mean ALB blood concentrations were significantly different between children 
with and without AEs (p < 0.05). A logistic regression analysis —controlled by age and 
sex— identified a significant association between AEs and ALB blood levels, with an OR = 
2.25 (95% CI: 1.26-3.99, p <0.05) for increments of 0.5 µg/mL of blood drug concentration. 
DISCUSSION 
This trial found a significant positive impact of high-dose IVM on the efficacy of ALB when 
co-administered at either single or 3-day regimens compared to the standard of practice in 
public health interventions. Despite the trial interruption due to the COVID-19 pandemic 
(117 children completed the trial, 53 did not), statistical differences still reached significance. 
This was due to the lower than estimated efficacy of the control arm (ALB 400 mg) and the 
higher than estimated efficacy of both IVM-containing arms (ALB/IVM 1-day and 
ALB/IVM 3-day). 
Previous studies have reported STH prevalences above 50% in multiple regions of Honduras 
[11, 22, 23] and according to a recent review, the country —despite MDA campaigns— has 
an overall STH prevalence >50% in 40.6% of its municipalities [12]. In the present study, T. 
trichiura is the most prevalent STH, in agreement with previous reports [13, 22, 23]. Only 
20% of T. trichiura infections in this study were of moderate or heavy intensity, as shown in 
previous reports from the same region [23]. 
Controlling T. trichiura infections remains challenging and new treatment approaches with 
adequate efficacies across STH are needed [24]. Multiple studies have explored the benefits 
of anthelminthic combination therapy [8, 25-29] and IVM has been of particular interest due 
to its broad-spectrum [10, 30, 31]. In fact, WHO has recently added IVM to its Essential  
Medicine List for the treatment of STH [32]. CRs in this trial demonstrate the superior 
efficacy of ALB+IVM at single-dose against trichuriasis, (88.6%) compared to a significantly 




















been previously documented [28], and although ALB efficacy improves if administered for 3 
days, it is still significantly lower than combined treatments. Through the determination of 
ALB plasma concentration, a low oral bioavailability of the product was ruled out to explain 
the low efficacy of ALB, which was found at levels consistent with previous ALB 
pharmacokinetic data [33, 34]. T. trichiura resistance to benzimidazoles remains to be 
investigated among the study participants, but a recent study in the same area documented the 
absence of β-tubulin related mutations [23]. 
Ascending doses (200 µg/kg, 400 µg/kg and 600 µg/kg) of IVM monotherapy have been 
recently studied versus placebo, demonstrating poor efficacies throughout the dosing range 
[26]. Our results on the systemic exposure of high-dose IVM are consistent with previous 
reports, although unlike them, we did not find a correlation between drug concentration and 
thinness (as assessed by BMIZ) [33], probably due to the homogeneity of BMIZ values in our 
study population and the high variability observed in blood drug concentrations. 
Safety of IVM and ALB has been widely demonstrated as both have been extensively used in 
MDA programs [35, 36]. Previous studies report a low frequency of AE, most of them of 
mild to moderate intensity [31]. Moreover, trials exploring the safety of combination therapy 
in comparison with ALB monotherapy do not report significant differences in the frequency 
or severity of AEs [8, 37]. Our results are not only consistent with previous data regarding 
ALB and IVM safety but suggest that combination therapy with a high dose of IVM could be 
safely administered to children. 
Similar to previous reports, the present trial did not identify any correlation between AEs and 
mean IVM systemic concentrations [10, 38].We did find, however, a significant association 
between ALB blood levels and AEs regardless of co-administration of IVM. This finding was 
unexpected and suggests that a greater absorption of ALB and its metabolites might result in 




















Among the limitations of this trial, we did not explore the added value of high-dose rather 
than standard doses of IVM. With the evidence generated by this and other studies on the 
safety of the high-dose regimen (600 µg/kg), future trials would be in a better position to 
tackle this question [26]. Although multiple Katz-Katz specimens might provide more 
precision to the baseline intensity of infection due to daily fluctuation in ova excretion, a 
single Kato-Katz as used in this study, has demonstrated adequate performance in drug-
efficacy assessments [39, 40]. Another limitation to consider is the study interruption due to 
the COVID-19 pandemic, which resulted in the recruitment of a smaller sample than the 
original target. Finally, larger studies are required to confirm our findings. 
In summary, the combined use of ALB and high-dose IVM shows a significant efficacy and 
good tolerability for the treatment of T. trichiura infections, thus offering a significantly 
improved treatment for the control of this STH species, which is notoriously refractory to the 
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Table 1. Characteristics of population recruited to participate in the study per treatment arm (n=117) 















Age — mean (SD) 8.8 (2.9) 




Girls 12 (50%) 15 (42.9%) 
10 
(55.6%) 
20 (50%) 0.835 
 Nutritional indicators      
Stunting (< -2 SD HAZ) 
9 (37.5%) 
7 (20%) 2 
(11.1%) 
11 (27.5%) 0.238 
Underweight (< -2 SD WAZ) c 2 (13.3%) 2 (8.3%) 0 (0%) 5 (16.1%) 0.543 
Thinness (< -2 SD BMIZ) 
1 (4.2%) 
1 (2.9%) 1 
(5.6%) 
0 (0%) 0.439 
Hemoglobin (g/dL) — mean (SD) 
13 (0.6) 
12.9 (0.8) 12.9 
(0.7) 
12.9 (0.8) 0.887 
b 
Parasitic profile      















Moderate-to-heavy infections by Trichuris 
trichiura  
3 (12.5%) 
7 (20%) 5 
(27.8%) 
10 (25%) 0.602 
a
 Calculated from Pearson Chi2 or Fisher’s exact test. 
b 
Calculated from one-way ANOVA. 
c 
Not calculated in 
children older than 10 years of age as per WHO recommendation (ALB, n=15; ALB+IVM, n=24; ALB x 3 
days, n=12; ALB+IVM x 3 days, n=31). SD: standard deviation; HAZ: height-for-age Z-scores; WAS: weight-





















Table 2. Cure rates and egg reduction rates for treatment arms (n=117) 
 Single dose 3-day dose 
 ALB (Control 
arm) 
ALB+IVM ALB ALB+IVM 
CURE RATE (CR)     
Positive before treatment 24 35 18 40 
Cured after treatment 1 31 6 40 
CR (95% CI) 4.2% (0.7-20.2) 88.6% (74.0-95.5) 33.3% (16.3-56.2) 100.0% (96.3-
100.0) 
P-value vs control arma - < 0.001 <0.05 <0.001 
EGG REDUCTION RATE (ERR)     








EPG After treatment — mean (95% CI) 732.9 (726.8-739.1) 54.2 (53.3-55.1) 343.9 (339.5-
348.4) 
0 
ERR (95% CI) 47.7% (46.8-48.7) 96.7% (96.2-96.9) 72.1% (71.2-73.0) 100.0% (96.3-
100.0) 
P-value vs control armb - <0.001 0.012 <0.001 
CR: Cure rate; EPG: eggs per gram of stool; ALB: albendazole IVM: Ivermectin  
a 
Calculated from Fisher’s exact test, 
b





















Table 3. Albendazole sulphoxide (ALBSO) and Ivermectin (IVM) blood concentration  
Single Dose 3-day dose 
 
ALB ALB+IVM ALB ALB+IVM 
  Day 1 Day 3 Day 1 Day 3 
ALBSO (µg/mL) 0.64 ± 0.24
a
 0.94 ± 0.57
a
 0.67 ± 0.25 0.66 ± 0.27 0.71 ± 0.25 0.76 ± 0.29 
Range 0.156-1.13 0.29-2.26 0.41-1.20 0.28-1.30 0.28-1.35 0.34-1.62 
IVM (ng/mL)  35.5 ± 17.9   42.9 ± 25.9 50.4 ± 29.7 
Range  9.17- 83.3   10-131.7 4.30-141.3 
Concentrations are expressed as (mean ± SD and range) measured at 4 h post-treatment in children treated with 
IVM (0.6 mg/kg) as a single oral dose (Arm 2) or during 3 consecutive days (Arm 4) and with albendazole 
(ALB, 400 mg) as a single oral dose (Arm 1 and 2) or during 3 consecutive days (Arm 3 and 4). 
a 





















Table 4. Safety profile for treatment arms (n=175) 
  Single dose 3-day dose   
 

































         
Photophobia  0 0 0 0 13 3 1.7 1 4 
Blurred vision 0 0 0 0 4.3 1 0 0 1 
Gastrointestinal 
disorders          
Abdominal pain  0 0 14 8 13 3 6.9 4 15 
Vomiting  0 0 0 0 0 0 3.4 2 2 
Diarrhea  0 0 1.8 1 0 0 0 0 1 
Respiratory 
disorders          
Common cold 0 0 0 0 4.3 1 1.7 1 2 
Cough 0 0 0 0 0 0 1.7 1 1 
Asthma 0 0 0 0 4.3 1 0 0 1 
General 
disorders          
Headache  0 0 8.8 5 8.7 2 13.8 8 15 
Nausea 0 0 1.8 1 0 0 0 0 1 
Pruritus  0 0 0 0 8.7 2 1.7 1 3 
Liver enzymes 
         
Grade 2 
toxicity* 
2.6 1 0 0 0 0 1.7 1 2 





















Figure 1. Flow diagram of the randomized controlled trial assessing efficacy and safety of 
albendazole and high-dose ivermectin co-administration in school-aged children infected 
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